171.03 0.00 (0.00%)
After hours: 4:50PM EDT
|Bid||163.53 x 900|
|Ask||176.13 x 800|
|Day's Range||163.30 - 171.26|
|52 Week Range||79.88 - 177.05|
|Beta (3Y Monthly)||3.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
The final winners are selected by the NEVYs Technology, Healthcare and Life Sciences Academies among a pool of nominees revealed in March. This year's seventh annual NEVYs marked the first time the Healthcare category had a dedicated Academy distinct from Life Sciences.
SAGE Therapeutics Inc NASDAQ NMS:SAGEView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is moderately high for SAGE with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.47 billion over the last one-month into ETFs that hold SAGE are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
In June, Zulresso — the first and only medicine approved by the Food and Drug Administration to specifically treat postpartum depression — will hit the market. Sage Therapeutics, the maker of the drug, now hopes to win the fight against another major issue: The public's misconception about mental health.
Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Analysts Are Feeling Good about These Biotech Stocks in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 26.25% for Sage Therapeutics (SAGE) based on the company’s
Biotech stocks are some of the most exciting investments on Wall Street. When one company develops a successful treatment for a complex condition, shares can surge overnight and attract buyout interest from Big Pharma. Case in point: Biotech giant Biogen (BIIB) imploded roughly 30% on Thursday after announcing it is canceling its Alzheimer’s drug efforts after poor drug trials.
, which just received FDA approval for Zulresso, the first treatment for postpartum depression. Dr. Jonas said that postpartum depression is the most common complication for women after childbirth, and suicide remains a leading cause of death among adults overall.
Shares of Sage Therapeutics Inc. rose 3% Wednesday morning after the company’s announcement Tuesday evening that the Food and Drug Administration had approved its drug for the treatment of postpartum depression.
Today was shaping up to be a bone-crushing session on Wall Street, Jim Cramer told his Mad Money viewers Wednesday. Without one, it will be a lot harder to own sectors like the industrials that need a strong global economy. Cramer explained that President Trump is taking a page from the Ronald Reagan playbook with Russia, "trust, but verify." The Chinese have a long history of not abiding by what they agree to, he said, which was evident most recently in the South China Sea.
Sage Therapeutics stock dipped Wednesday after the FDA approved its postpartum depression treatment, Zulresso. Investors are now looking at another depression drug called SAGE-217.
Sage said the FDA approved its Zulresso — chemically brexanolone — an injection for the treatment of postpartum depression. Zulresso has both Priority Review status as well as a Breakthrough Therapy Designation from the FDA. "The potential to rapidly reduce symptoms in this critical disorder is an exciting milestone in women's mental health," said Samantha Meltzer, the primary investigator of the Zulresso clinical trials.
According to the Centers for Disease Control and Prevention, 1 in 9 women in the United States experience symptoms of postpartum depression. Looking at individual states, postpartum depression can affect as many as 1 in 5 women. In March 2019, the FDA approved the first postpartum depression drug, developed by Sage Therapeutics. Led by CEO Jeff Jonas, Sage Therapeutics created the treatment by taking a different approach toward mental health.
Jim Cramer talks with Sage Therapeutics CEO Jeff Jonas about the biopharma company's Zulresso drug for postpartum depression and how it could help mothers.
The FDA approved the first-ever drug to treat postpartum depression. The drug, created by Sage Therapeutics, can be delivered as a one-time infusion into a woman’s veins over the course of 2 days. Yahoo Finance’s Alexis Christoforous shares just how much it’ll cost.